コンテンツへスキップ
Merck
  • A 12-year survey of methicillin-resistant Staphylococcus aureus infections in Greece: ST80-IV epidemic?

A 12-year survey of methicillin-resistant Staphylococcus aureus infections in Greece: ST80-IV epidemic?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2014-04-23)
E Drougka, A Foka, A Liakopoulos, A Doudoulakakis, E Jelastopulu, V Chini, A Spiliopoulou, S Levidiotou, T Panagea, A Vogiatzi, E Lebessi, E Petinaki, I Spiliopoulou
要旨

Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of both healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA) infections. Severe MRSA infections have been associated with the virulence factor Panton-Valentine leukocidin (PVL). The aim of this study was to investigate susceptibility patterns, the presence of toxin genes, including that encoding PVL, and clonality among MRSA isolates collected from patients in Greece over a 12-year period. MRSA isolates were collected from January 2001 to December 2012 from six different hospitals. Antibiotic susceptibility was determined with the disk diffusion method and the Etest. The presence of the toxic shock syndrome toxin-1 gene (tst), the enterotoxin gene cluster (egc) and the PVL gene was tested with PCR. The genotypic characteristics of the strains were analysed by SCCmec and agr typing, and clonality was determined with pulsed-field gel electrophoresis and multilocus sequence typing. An increasing rate of MRSA among S. aureus infections was detected up to 2008. The majority of PVL-positive MRSA isolates belonged to a single clone, sequence type (ST)80-IV, which was disseminated both in the community and in hospitals, especially during the warmest months of the year. Carriage of tst was associated with ST30-IV, whereas egc was distributed in different clones. CA-MRSA isolates were recovered mainly from skin and soft tissue infections, whereas HA-MRSA isolates were associated with surgical and wound infections. During the period 2001-2012, ST80-IV predominated in the community and infiltrated the hospital settings in Greece, successfully replacing other PVL-positive clones. The predominance of ST239-III in HA-MRSA infections was constant, whereas new clones have also emerged. Polyclonality was statistically significantly higher among CA-MRSA isolates and isolates from adult patients.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リファンピシン, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
エリスロマイシン, BioReagent, suitable for cell culture
Sigma-Aldrich
トリメトプリム, ≥98.5%
Sigma-Aldrich
トリメトプリム, ≥99.0% (HPLC)
Sigma-Aldrich
リファンピシン, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
トブラマイシン, Aminoglycoside antibiotic
Supelco
トリメトプリム, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
ダプトマイシン, cyclic lipopeptide antibiotic
Supelco
トブラマイシン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
Sigma-Aldrich
エリスロマイシン, potency: ≥850 μg per mg
USP
トブラマイシン, United States Pharmacopeia (USP) Reference Standard
Supelco
エリスロマイシン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
フシジン酸
Supelco
トリメトプリム, VETRANAL®, analytical standard
USP
エリスロマイシン, United States Pharmacopeia (USP) Reference Standard
USP
トリメトプリム, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
エリスロマイシン, meets USP testing specifications
リファンピシン, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
エリスロマイシン, tested according to Ph. Eur.
トブラマイシン, European Pharmacopoeia (EP) Reference Standard
トリメトプリム, European Pharmacopoeia (EP) Reference Standard